Abstract
Human immunodeficiency virus (HIV)-1 Nef is a regulatory protein critically involved in AIDS pathogenesis. We previously demonstrated that extracellular Nef is efficiently internalized by human primary monocyte-derived macrophages (MDMs), thereby activating a number of transcription factors including STATs, MAPKs, IRF-3, and NF-κB. Such an activation state leads to the release of inflammatory factors whose paracrine effects deserve deep consideration. Here, we demonstrate that quiescent CD4 lymphocytes undergo cell activation when cultivated in supernatants from autologous MDMs treated with extracellular wt Nef but not with its counterpart mutated in the 72PxxP75 polyproline domain. Of a pathogenetic relevance, this effect coupled with the sensitization of quiescent CD4 lymphocytes to HIV-1 infection. By microarray assay, we found that the CCL24/eotaxin-2 gene was up-regulated in MDMs treated with wt Nef but not with the 72AxxA75 mutant. In addition, the higher transcription activity correlated with a significant increase of the CCL24/Eotaxin-2 release. Finally, we observed that anti-CCL24/eotaxin-2 antibodies efficiently neutralized the stimulatory effect on CD4 lymphocytes of supernatants from MDMs treated with extracellular Nef. Overall, these data support the idea that CCL24/eotaxin-2 is part of the mechanism of CD4 lymphocyte activation paracrinally induced by Nef.
Keywords: Macrophages, HIV-1, nef, microarray, CCL24/eotaxin-2
Current Drug Discovery Technologies
Title: Microarray Analysis Reveals CCL24/Eotaxin-2 as an Effector of the Pathogenetic Effects Induced by HIV-1 Nef
Volume: 4 Issue: 1
Author(s): Gianna Fiorucci, Eleonora Olivetta, Maria Vincenza Chiantore and Maurizio Federico
Affiliation:
Keywords: Macrophages, HIV-1, nef, microarray, CCL24/eotaxin-2
Abstract: Human immunodeficiency virus (HIV)-1 Nef is a regulatory protein critically involved in AIDS pathogenesis. We previously demonstrated that extracellular Nef is efficiently internalized by human primary monocyte-derived macrophages (MDMs), thereby activating a number of transcription factors including STATs, MAPKs, IRF-3, and NF-κB. Such an activation state leads to the release of inflammatory factors whose paracrine effects deserve deep consideration. Here, we demonstrate that quiescent CD4 lymphocytes undergo cell activation when cultivated in supernatants from autologous MDMs treated with extracellular wt Nef but not with its counterpart mutated in the 72PxxP75 polyproline domain. Of a pathogenetic relevance, this effect coupled with the sensitization of quiescent CD4 lymphocytes to HIV-1 infection. By microarray assay, we found that the CCL24/eotaxin-2 gene was up-regulated in MDMs treated with wt Nef but not with the 72AxxA75 mutant. In addition, the higher transcription activity correlated with a significant increase of the CCL24/Eotaxin-2 release. Finally, we observed that anti-CCL24/eotaxin-2 antibodies efficiently neutralized the stimulatory effect on CD4 lymphocytes of supernatants from MDMs treated with extracellular Nef. Overall, these data support the idea that CCL24/eotaxin-2 is part of the mechanism of CD4 lymphocyte activation paracrinally induced by Nef.
Export Options
About this article
Cite this article as:
Gianna Fiorucci , Eleonora Olivetta , Maria Vincenza Chiantore and Maurizio Federico , Microarray Analysis Reveals CCL24/Eotaxin-2 as an Effector of the Pathogenetic Effects Induced by HIV-1 Nef, Current Drug Discovery Technologies 2007; 4 (1) . https://dx.doi.org/10.2174/157016307781115502
DOI https://dx.doi.org/10.2174/157016307781115502 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HDL Stimulates apoM Secretion
Protein & Peptide Letters The Immune System as a Therapeutic Target for Old and New Drugs in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Modulation of Human Keratinocyte Responses to Solar UV by Plant Polyphenols As a Basis for Chemoprevention of Non-Melanoma Skin Cancers
Current Medicinal Chemistry Pyrazoles as Promising Scaffold for the Synthesis of Anti-Inflammatory and/or Antimicrobial Agent: A Review
Mini-Reviews in Medicinal Chemistry The Neonatal Immune System: General Concepts and Clinical Correlations
Current Immunology Reviews (Discontinued) Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Hypersensitivity to Febuxostat in a Patient with a Previous Allopurinolinduced Steven-Johnson Syndrome: A Case Report of Treatment with a Slow Desensitization Protocol
Endocrine, Metabolic & Immune Disorders - Drug Targets Hepatic Angiogenesis and Fibrogenesis in the Progression of Chronic Liver Diseases
Current Angiogenesis (Discontinued) Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future
Current Stem Cell Research & Therapy Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy)
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Current Vascular Pharmacology Synthesis, Structure Activity Relationship (SAR), and Biological Activities of Benzylideneacetophenones Derivatives
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Cholecystokinin-8 and Nerve Growth Factor: two Endogenous Molecules Working for the Upkeep and Repair of the Nervous System
Current Drug Targets - CNS & Neurological Disorders Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Future Target Molecules for Influenza Treatment
Mini-Reviews in Medicinal Chemistry Role of Nanotechnology in Delivery of Protein and Peptide Drugs
Current Pharmaceutical Design Oncolytic Viruses: The Best is Yet to Come
Current Cancer Drug Targets Cytokine Modulation for Anti-Allergic Treatment
Current Pharmaceutical Design